CoChat

Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure

Open access
Anand, Inder S., Bishu, Kalkidan, Rector, Thomas S., Ishani, Areef, Kuskowski, Michael A., Cohn, Jay N. · 2009 · Circulation
Cited by 145

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background— Chronic kidney disease (CKD) is an established risk factor for poor outcomes in heart failure (HF). Whether proteinuria provides additional prognostic information is not known. Renin-angiotensin blockade medications improve outcomes in HF but are underutilized in HF patients with renal dysfunction because of safety concerns and a lack of evidence of their effectiveness. Methods and Results— In the Valsartan in Heart Failure Trial (Val-HeFT), 5010 patients with class II, III, or IV heart failure were randomly assigned to receive valsartan or placebo. The 2 primary outcomes were death and first morbid event, defined as death, sudden death with resuscitation, hospitalization for HF, or administration of intravenous inotropic or vasodilator drugs for 4 hours or more without hospitalization. The study cohort was divided into subgroups according to the presence of CKD (estimated glomerular filtration rate <60 mL · min −1 · 1.73 m −2 ) and proteinuria (positive dipstick). Multivariable Cox proportional hazards regression models were used to examine the relationships between study outcomes and proteinuria, including its interaction with CKD. The interaction between valsartan and CKD was also tested. The effect of valsartan on estimated glomerular filtration rate was estimated by generalized linear models, including tests of interactions between treatment and CKD. At baseline, CKD was found in 58% and dipstick-positive proteinuria in 8% of patients. Dipstick-positive proteinuria was independently associated with mortality (hazard ratio [HR] 1.28, 95% confidence interval [CI] 1.01 to 1.62, P =0.05) and first morbid event (HR 1.28, 95% CI 1.06 to 1.55, P =0.01). The increased risk of death associated with dipstick-positive proteinuria was similar for those with and without CKD (HR 1.26, 95% CI 0.96 to 1.66 versus HR 1.37, 95% CI 0.83 to 2.26; P =0.94), as was the hazard for first morbid event (HR 1.26, 95% CI 1.01 to 1.57 versus HR 1.42, 95% CI 0.98 to 2.07; P =0.71). Valsartan reduced estimated glomerular filtration rate compared with placebo to a similar extent ( P =0.52) in the subgroups with CKD (mean reduction −3.6 mL · min −1 · 1.73 m −2 ) and without CKD (mean reduction −4.0 mL · min −1 · 1.73 m −2 ) and by −3.8 mL · min −1 · 1.73 m −2 in both groups combined. The beneficial effect of valsartan on first morbid events was similar in those with and without CKD (HR 0.86, 95% CI 0.74 to 0.99 versus HR 0.91, 95% CI 0.73 to 1.12; P =0.23) and was significant in the subgroup with CKD. The effect of valsartan on mortality did not differ in patients with and without CKD (HR 1.01, 95% CI 0.85 to 1.20 versus HR 0.91, 95% CI 0.69 to 1.25; P =0.08). Conclusions— CKD was common and dipstick-positive proteinuria was infrequent in this sample of patients with HF. After controlling for other risk factors, including CKD, the relatively small subgroup with dipstick-positive proteinuria did have worse outcomes. Valsartan reduced the estimated glomerular filtration rate by the same amount in patients with and without CKD and reduced the risk of the first morbid event in patients with CKD, which suggests its beneficial effects in patients with HF and CKD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.109.853648

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 34

  1. 10.1161/circulationaha.107.188511 · DOI · Paper page
  2. 10.1161/circ.102.2.203 · doi:10.1161/circ.102.2.203
  3. 10.1097/01.ASN.0000135121.81744.75 · DOI
  4. 10.1016/S0735-1097(99)00608-7 · DOI · Paper page
  5. 10.1681/ASN.2005030270 · DOI
  6. 10.1016/j.ahj.2004.02.007 · doi:10.1016/j.ahj.2004.02.007
  7. 10.1016/j.amjcard.2006.08.042 · DOI · Paper page
  8. 10.1161/01.cir.0000116764.53225.a9 · DOI · Paper page
  9. 10.1016/j.jacc.2004.06.072 · DOI · Paper page
  10. 10.1097/01.ASN.0000018409.45834.FA · DOI · Paper page
  11. 10.1016/j.ahj.2007.03.017 · DOI
  12. 10.1001/archinte.167.18.1930 · DOI · Paper page
  13. 10.1161/01.cir.0000149806.01354.bf · DOI · Paper page
  14. 10.1016/j.cardfail.2005.05.007 · DOI
  15. Ellekilde G, Holm J, von Eyben FE, Hemmingsen L. Above-normal urinary excretion of albumin and retinol-binding protein in chronic heart failure. Clin Chem. 1992; 38: 593–594.
  16. 10.1159/000166727 · DOI
  17. 10.1136/bmj.38814.566019.2F · DOI · Paper page
  18. 10.1681/ASN.V133745 · DOI · Paper page
  19. 10.1038/ki.1996.481 · DOI · Paper page
  20. 10.1046/j.1523-1755.1998.00874.x · DOI · Paper page
  21. 10.1111/j.1523-1755.2004.00653.x · DOI · Paper page
  22. 10.1161/01.cir.0000139860.33974.28 · DOI · Paper page
  23. Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F, Goldhaber S, Lewis EJ, Pfeffer MA. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl. Nov 2004: S50–S55.
  24. 10.7326/0003-4819-139-11-200312020-00008 · DOI · Paper page
  25. 10.7326/0003-4819-148-1-200801010-00190 · DOI · Paper page
  26. 10.1016/S0140-6736(08)61236-2 · DOI · Paper page
  27. 10.7326/0003-4819-130-6-199903160-00002 · DOI · Paper page
  28. 10.1053/ajkd.2002.29865 · DOI · Paper page
  29. 10.1093/aje/kwn033 · DOI · Paper page
  30. 10.1681/ASN.2006050517 · DOI · Paper page
  31. 10.1161/circulationaha.107.723270 · DOI · Paper page
  32. 10.1111/j.1464-410X.1989.tb05166.x · DOI
  33. 10.1172/JCI103127 · DOI · Paper page
  34. 10.1056/NEJM198204293061706 · doi:10.1056/nejm198204293061706

Cited by

See all 145

Metadata

Authors
Anand, I. S., Bishu, K., Rector, T. S., Ishani, A., Kuskowski, M. A., & Cohn, J. N.
Venue
Circulation
Published
2009-10-20
Volume
120
Issue
16
Pages
1577-1584
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2104402487
Cited by
145
References
4
FWCI
7.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.